A novel therapeutic vaccine of GM-CSF/TNFα surface-modified RM-1 cells against the orthotopic prostatic cancer

Abstract A novel therapeutic vaccine against prostate cancer was developed by simultaneous immobilization of streptavidin-tagged bioactive GM-CSF and TNFα on the biotinylated surface of 30% ethanol-fixed RM-1 prostatic cancer cells. This study showed that the GM-CSF/TNFα-doubly surface-modified vacc...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 28; no. 31; pp. 4937 - 4944
Main Authors Yin, Weihua, He, Qiushan, Hu, Zhiming, Chen, Zhong, Qifeng, Mao, Zhichun, Song, Zhihui, Qu, Xiaoxia, Nie, Li, Jinlong, Gao, Jimin
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 01.07.2010
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract A novel therapeutic vaccine against prostate cancer was developed by simultaneous immobilization of streptavidin-tagged bioactive GM-CSF and TNFα on the biotinylated surface of 30% ethanol-fixed RM-1 prostatic cancer cells. This study showed that the GM-CSF/TNFα-doubly surface-modified vaccine significantly extended the survival in the orthotopic model of RM-1 prostate cancer, and was superior to single GM-CSF- or TNFα-surface-modified vaccine. Moreover, the splenocytes from the GM-CSF/TNFα-vaccine-treated mice showed the most potent cytotoxicity on RM-1 cells and the highest production of RM-1-specific IFNγ. In addition, more CD4+ and CD8+ T cells infiltrated into the tumor sites in the GM-CSF/TNFα-vaccine-treated mice than in the GM-CSF- or TNFα-vaccine-treated mice. Therefore, our study demonstrated that the efficacy of RM-1 prostate cancer cell vaccine could be improved by conjugating both GM-CSF and TNFα simultaneously on the surface of cancer cells, and that this modification thus has a potential translational significance.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2010.05.038